Renin-angiotensin-aldosterone system inhibitors and COVID-19.
作者信息
Quinn Kieran L, Fralick Michael, Zipursky Jonathan S, Stall Nathan M
机构信息
Department of Medicine (Quinn, Fralick, Zipursky, Stall), University of Toronto; Division of General Internal Medicine and Geriatrics (Quinn, Fralick, Stall), Sinai Health System; Institute of Health Policy, Management and Evaluation (Quinn, Zipursky, Stall), University of Toronto; Division of Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre, Toronto, Ont.
出版信息
CMAJ. 2020 May 19;192(20):E553-E554. doi: 10.1503/cmaj.200619. Epub 2020 Apr 24.
Abstract
摘要
相似文献
1
Renin-angiotensin-aldosterone system inhibitors and COVID-19.肾素-血管紧张素-醛固酮系统抑制剂与2019冠状病毒病
CMAJ. 2020 May 19;192(20):E553-E554. doi: 10.1503/cmaj.200619. Epub 2020 Apr 24.
2
Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.肾素-血管紧张素-醛固酮系统抑制剂治疗高血压患者可降低COVID-19死亡率：一项荟萃分析
Hypertension. 2020 Aug;76(2):e13-e14. doi: 10.1161/HYPERTENSIONAHA.120.15572. Epub 2020 May 27.
3
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
4
The Renin-Angiotensin-Aldosterone System in Coronavirus Infection-Current Considerations During the Pandemic.冠状病毒感染中的肾素-血管紧张素-醛固酮系统——大流行期间的当前思考
J Cardiothorac Vasc Anesth. 2020 Jul;34(7):1717-1719. doi: 10.1053/j.jvca.2020.04.010. Epub 2020 Apr 16.
5
Risk and prognosis of COVID-19 in patients treated with renin-angiotensin-aldosterone inhibitors.接受肾素-血管紧张素-醛固酮抑制剂治疗的COVID-19患者的风险及预后
Eur J Anaesthesiol. 2020 Sep;37(9):739-742. doi: 10.1097/EJA.0000000000001277.
6
Related molecular mechanisms of COVID-19, hypertension, and diabetes.新型冠状病毒肺炎、高血压和糖尿病的相关分子机制
Am J Physiol Endocrinol Metab. 2020 Jun 1;318(6):E881. doi: 10.1152/ajpendo.00164.2020.
7
Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.肾素-血管紧张素系统抑制剂对新型冠状病毒肺炎中2019冠状病毒感染及肺损伤的潜在差异影响
Hypertens Res. 2020 Aug;43(8):837-840. doi: 10.1038/s41440-020-0478-1. Epub 2020 May 20.
8
[Renin-angiotensin system blockers and COVID-19 infection].[肾素-血管紧张素系统阻滞剂与新型冠状病毒肺炎感染]
Hipertens Riesgo Vasc. 2020 Jul-Sep;37(3):99-100. doi: 10.1016/j.hipert.2020.04.002. Epub 2020 Apr 16.
9
[Hypertension and RAAS inhibition in times of COVID-19 - current recommendations of the European Society of Hypertension.].[2019冠状病毒病时期的高血压与肾素-血管紧张素-醛固酮系统抑制——欧洲高血压学会的当前建议。]
MMW Fortschr Med. 2020 May;162(9):67-69. doi: 10.1007/s15006-020-0483-y.
10
A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.中国 2 家中心回顾性研究：血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂在高血压合并 COVID-19 患者中的持续使用效果。
Med Sci Monit. 2020 Sep 24;26:e926651. doi: 10.12659/MSM.926651.
引用本文的文献
1
Evaluation of Possible Association between Serum Levels of Aldosterone and Cortisol with Clinical Symptoms Progression in COVID-19 Suspicious Outpatients Tested for SARS-CoV2 RT-PCR: An Analytical Cross-Sectional Study.评估 COVID-19 疑似门诊患者 SARS-CoV2 RT-PCR 检测中醛固酮和皮质醇血清水平与临床症状进展的可能相关性：一项分析性横断面研究。
Arch Razi Inst. 2023 Jun 30;78(3):923-933. doi: 10.22092/ARI.2021.356094.1774. eCollection 2023 Jun.
2
The Renin-Angiotensin-Aldosterone System, Nitric Oxide, and Hydrogen Sulfide at the Crossroads of Hypertension and COVID-19: Racial Disparities and Outcomes.肾素-血管紧张素-醛固酮系统、一氧化氮和硫化氢在高血压和 COVID-19 的交叉点：种族差异和结果。
Int J Mol Sci. 2022 Nov 11;23(22):13895. doi: 10.3390/ijms232213895.
3
Biologia Futura: is ADAM 17 the reason for COVID-19 susceptibility in hyperglycemic and diabetic patients?未来生物学：ADAM17 是否是糖尿病和高血糖患者易感染 COVID-19 的原因？
Biol Futur. 2021 Sep;72(3):291-297. doi: 10.1007/s42977-021-00092-2. Epub 2021 Jun 8.
4
Comparison of Medication Prescribing Before and After the COVID-19 Pandemic Among Nursing Home Residents in Ontario, Canada.比较 COVID-19 大流行前后加拿大安大略省养老院居民的用药情况。
JAMA Netw Open. 2021 Aug 2;4(8):e2118441. doi: 10.1001/jamanetworkopen.2021.18441.
5
Translating bioactive peptides for COVID-19 therapy.用于 COVID-19 治疗的生物活性肽的翻译。
Eur J Pharmacol. 2021 Jan 5;890:173661. doi: 10.1016/j.ejphar.2020.173661. Epub 2020 Oct 21.
6
SARS-CoV-2 and the cardiovascular system.严重急性呼吸综合征冠状病毒 2 型与心血管系统。
Clin Chim Acta. 2020 Nov;510:311-316. doi: 10.1016/j.cca.2020.07.019. Epub 2020 Jul 16.
7
Renin-angiotensin-aldosterone system inhibitors to treat COVID-19?肾素-血管紧张素-醛固酮系统抑制剂用于治疗新型冠状病毒肺炎？
CMAJ. 2020 Jun 29;192(26):E728. doi: 10.1503/cmaj.76023.
8
Further developments in the literature on RAAS inhibitors and COVID-19.关于肾素-血管紧张素-醛固酮系统（RAAS）抑制剂与2019冠状病毒病（COVID-19）的文献的进一步进展。
CMAJ. 2020 Jun 29;192(26):E727. doi: 10.1503/cmaj.76076.
9
Association between angiotensin blockade and COVID-19 severity in Hong Kong.香港地区血管紧张素阻断与新冠病毒疾病严重程度之间的关联
CMAJ. 2020 Jun 8;192(23):E635. doi: 10.1503/cmaj.75865.
10
Good things come in threes (and sometimes fours): Update on renin-angiotensin-aldosterone system inhibitors and COVID-19.好事成三（有时成四）：肾素-血管紧张素-醛固酮系统抑制剂与2019冠状病毒病的最新情况
CMAJ. 2020 Jun 1;192(22):E611. doi: 10.1503/cmaj.75720.
本文引用的文献
1
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
2
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
3
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?新型冠状病毒肺炎与血管紧张素转换酶抑制剂及血管紧张素受体阻滞剂：证据是什么？
JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812.
4
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
5
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.中国武汉 2019 年冠状病毒病肺炎患者急性呼吸窘迫综合征和死亡的相关危险因素。
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
6
Preventing a covid-19 pandemic.预防新冠疫情。
BMJ. 2020 Feb 28;368:m810. doi: 10.1136/bmj.m810.
7
The 2017 Clinical Practice Guideline for High Blood Pressure.《2017年高血压临床实践指南》
JAMA. 2017 Dec 5;318(21):2073-2074. doi: 10.1001/jama.2017.18209.
8
Immortal time bias in pharmaco-epidemiology.药物流行病学中的不朽时间偏倚。
Am J Epidemiol. 2008 Feb 15;167(4):492-9. doi: 10.1093/aje/kwm324. Epub 2007 Dec 3.
Zotero 插件